Latest Period
Q1 2026
Security Snapshot
Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value (ELDN) Institutional Ownership
CUSIP: 28617K101
13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026
Institutions Reporting
120
Shares (Excl. Options)
42,619,679
Price
$3.08
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value
- Symbol
- ELDN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 42,619,679
- Total 13F value
- $131,231,289
- Portfolio coverage rank
- 0%
- Share change
- -1,745,248
- Value change
- -$2,467,597
- Number of holders
- 120
- Shares outstanding
- 78,762,953
- SEC-reported price per share
- $3.94
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ELDN - Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 28617K101.
- 120 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 120 to 8 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $131,231,289 to $610,019.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 120 institutions filings for Q1 2026.
Security key
28617K101
Latest holder period
Q1 2026
13F holders
120
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
ELDN full holder history
Eledon Pharmaceuticals, Inc. SEC filings
Eledon Pharmaceuticals, Inc. company facts
Eledon Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28617K101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
ELDN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 10% | $25,336,309 | 7,868,419 | BVF PARTNERS L P/IL | 31 Mar 2026 | |||
| BlackRock, Inc. | 5.8% | +24% | $13,493,040 | +$2,325,502 | 4,380,857 | +21% | BlackRock, Inc. | 31 Mar 2026 |
| Coastlands Capital LP | 5% | -16% | $6,733,682 | -$1,410,519 | 3,937,826 | -17% | Coastlands Capital LP | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC | 5% | $10,259,798 | 3,137,553 | Armistice Capital, LLC | 31 Dec 2024 | |||
| Frazier Life Sciences Public Fund, L.P. | 2% | $3,847,923 | 1,176,735 | James N. Topper | 31 Dec 2024 |
As of 31 Mar 2026, 120 institutional investors reported holding 42,619,679 shares of Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value (ELDN). This represents 54% of the company’s total 78,762,953 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
51%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 8% | 6,293,282 | 0% | 0.62% | $19,383,309 |
| BlackRock, Inc. | 5.6% | 4,382,245 | +21% | 0% | $13,497,314 |
| Defilade Capital Management, L.P. | 4.5% | 3,564,127 | +8.3% | 1.5% | $10,977,511 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 3,293,134 | 0% | 0% | $10,142,853 |
| Ensign Peak Advisors, Inc | 3.1% | 2,464,919 | 0% | 0.01% | $7,591,951 |
| Zimmer Partners, LP | 2.4% | 1,875,000 | -21% | 0.14% | $5,775,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 1,791,783 | +26% | 0% | $5,520,050 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.2% | 1,772,131 | -17% | 0.94% | $5,458,163 |
| Catalio Capital Management, LP | 2.1% | 1,639,816 | +30% | 1.1% | $5,050,633 |
| Blue Owl Capital Holdings LP | 1.8% | 1,419,912 | -26% | 1.2% | $4,373,329 |
| STATE STREET CORP | 1.5% | 1,154,671 | +49% | 0% | $3,556,387 |
| AWM Investment Company, Inc. | 1.4% | 1,100,000 | 0% | 0.38% | $3,388,000 |
| Jefferies Financial Group Inc. | 1.4% | 1,094,456 | -31% | 0.04% | $3,370,924 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.3% | 1,039,275 | 0% | 0.54% | $3,200,967 |
| ADAR1 Capital Management, LLC | 1.2% | 974,421 | -47% | 0.18% | $3,001,217 |
| BANK OF AMERICA CORP /DE/ | 1.1% | 869,544 | +1347% | 0% | $2,678,195 |
| Sanofi | 1% | 814,980 | 0% | 0.75% | $2,510,138 |
| CM Management, LLC | 0.83% | 650,000 | 0% | 1.7% | $2,002,000 |
| 22NW, LP | 0.81% | 636,364 | 0% | 1.5% | $1,960,001 |
| SG Americas Securities, LLC | 0.81% | 635,845 | +1.3% | 0% | $1,958,000 |
| UBS Group AG | 0.7% | 547,447 | -7.7% | 0% | $1,686,137 |
| NORTHERN TRUST CORP | 0.69% | 543,842 | +27% | 0% | $1,675,033 |
| VANGUARD FIDUCIARY TRUST CO | 0.64% | 503,764 | 0% | 0% | $1,551,593 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.55% | 429,889 | 0% | 0% | $1,324,058 |
| GOLDMAN SACHS GROUP INC | 0.47% | 370,090 | +86% | 0% | $1,139,877 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 154,827 | $610,019 | +$392,011 | $3.94 | 8 |
| 2026 Q1 | 42,619,679 | $131,231,289 | -$2,467,597 | $3.08 | 120 |
| 2025 Q4 | 44,151,425 | $66,693,538 | -$4,536,835 | $1.51 | 95 |
| 2025 Q3 | 36,469,559 | $94,453,818 | -$12,219,070 | $2.59 | 82 |
| 2025 Q2 | 40,843,175 | $110,685,079 | +$5,557,133 | $2.71 | 85 |
| 2025 Q1 | 38,448,901 | $130,340,726 | -$2,283,033 | $3.39 | 83 |
| 2024 Q4 | 38,479,556 | $158,542,263 | +$81,995,653 | $4.12 | 75 |
| 2024 Q3 | 18,485,827 | $46,028,922 | +$410,879 | $2.49 | 33 |
| 2024 Q2 | 18,259,810 | $48,206,187 | +$22,892,459 | $2.64 | 31 |
| 2024 Q1 | 9,595,061 | $19,765,324 | +$914,973 | $2.06 | 28 |
| 2023 Q4 | 9,153,168 | $16,475,058 | +$507,102 | $1.80 | 28 |
| 2023 Q3 | 8,917,722 | $12,217,005 | -$186,914 | $1.37 | 28 |
| 2023 Q2 | 9,275,200 | $12,707,758 | +$2,932,975 | $1.37 | 32 |
| 2023 Q1 | 6,240,661 | $14,727,632 | -$15,081 | $2.36 | 29 |
| 2022 Q4 | 6,249,494 | $14,377,182 | -$299,603 | $2.28 | 27 |
| 2022 Q3 | 6,267,437 | $17,296,971 | -$726,076 | $2.76 | 26 |
| 2022 Q2 | 6,534,650 | $15,944,119 | -$1,242,145 | $2.44 | 27 |
| 2022 Q1 | 7,004,967 | $27,598,192 | -$4,350,190 | $3.94 | 30 |
| 2021 Q4 | 7,884,710 | $34,745,775 | -$3,532,209 | $4.41 | 34 |
| 2021 Q3 | 8,434,281 | $52,121,569 | -$6,530,652 | $6.18 | 29 |
| 2021 Q2 | 9,423,304 | $74,527,000 | +$5,445,356 | $7.91 | 29 |
| 2021 Q1 | 8,317,680 | $88,956,000 | +$88,566,000 | $10.70 | 32 |
| 2020 Q4 | 36,111 | $556,000 | +$556,000 | $15.40 | 1 |